Nutrients

Search documents
dsm-firmenich achieves target of 100% purchased renewable electricity
Globenewswire· 2025-09-03 05:00
Core Insights - dsm-firmenich has achieved its goal of sourcing 100% of purchased electricity from renewable sources ahead of its 2025 target, marking a significant milestone in its sustainability strategy [1][2][3] Group 1: Sustainability Goals - The company aims to reach net-zero greenhouse gas emissions across its operations and value chain by 2045, validated by the Science Based Targets initiative [2][3] - The achievement of 100% renewable electricity sourcing is part of a broader commitment to maintain this level through 2030 [2] Group 2: Leadership Statements - CEO Dimitri de Vreeze emphasized that this milestone reflects the company's decisive actions and dedication towards sustainability [3] - Chief Sustainability Officer Katharina Stenholm acknowledged the ongoing journey towards long-term goals, highlighting the importance of collective effort [3] Group 3: Sourcing Strategy - dsm-firmenich's strategy included long-term power purchase agreements with large wind and solar farms in Europe and North America, as well as local retail contracts [4] - The company is also increasing renewable purchases in China through several long-term contracts [4] Group 4: Broader Energy Focus - In addition to renewable electricity, dsm-firmenich is expanding its focus on renewable steam and heat from sustainably sourced biomass co-generation plants in multiple countries [5] - The company is optimizing waste streams and collaborating on new low-carbon solutions as part of its greenhouse gas reduction program [5] Group 5: Company Overview - dsm-firmenich operates in the nutrition, health, and beauty sectors, with revenues exceeding €12 billion and a workforce of nearly 30,000 employees [6]
Balchem Corporation Reports Second Quarter 2025 Financial Results
Globenewswire· 2025-07-31 11:00
Core Insights - Balchem Corporation reported record financial results for the second quarter of 2025, with net sales of $255.5 million, net earnings of $38.3 million, and adjusted EBITDA of $69.2 million, reflecting strong growth across all reporting segments [1][2][4][7]. Financial Performance - Net sales increased by $21.4 million, or 9.1%, compared to the prior year quarter [7]. - GAAP net earnings rose by 19.4% to $38.3 million from $32.1 million in the prior year quarter [7]. - Adjusted EBITDA reached a record $69.2 million, an increase of 11.2% from the previous year [7]. - Diluted net earnings per share were $1.17, up from $0.98 in the prior year quarter, while adjusted earnings per share were $1.27 compared to $1.09 [7][8]. Segment Performance - The Human Nutrition and Health segment generated record sales of $160.8 million, an increase of 8.7%, with earnings from operations rising by 14.9% to $38.3 million [9]. - The Animal Nutrition and Health segment reported sales of $56.0 million, a 13.1% increase, with earnings from operations growing by 30.5% to $3.5 million [10]. - The Specialty Products segment achieved record sales of $37.2 million, a 6.0% increase, with earnings from operations slightly up by 0.4% to $11.3 million [11]. Cash Flow and Investments - Cash flows from operations were $47.3 million, with free cash flow of $40.7 million [7][14]. - The company announced plans to build a new $36 million micro-encapsulation manufacturing facility in Orange County, NY, which will more than double its capacity for micro-encapsulation technologies [7]. Market Environment - The European Commission's decision to impose provisional anti-dumping duties of 95.4% to 120.8% on choline chloride imports from China is expected to create a more competitive market environment for Balchem [4][7].
3 Ancillary Cannabis Stocks Set to Benefit from Industry Growth in 2025
Marijuana Stocks | Cannabis Investments And News. Roots Of A Budding Industry.™· 2025-07-17 14:00
Industry Overview - The U.S. legal cannabis market is projected to reach nearly $45 billion by 2025, with continued double-digit growth expected over the next several years [1] - State-level legalization is gaining momentum, with bipartisan bills being introduced more frequently, contributing to a positive long-term outlook despite federal reform uncertainties [2] Company Summaries GrowGeneration Corp. (GRWG) - GrowGeneration operates over 70 stores across 22 states, focusing on hydroponic and garden supply retail, with a significant presence in California, Colorado, Florida, Michigan, and New York [3] - In Q1 2025, GrowGeneration reported net revenue of $35.7 million, a year-over-year decline, but improved gross margin to 27.2% through better inventory management and reduced discounting [7] - The company maintained strong liquidity with over $50 million in cash and no debt, despite a net loss of $9.4 million [8] Hydrofarm Holdings Group, Inc. (HYFM) - Hydrofarm is a leading manufacturer and distributor of hydroponic equipment, operating nine distribution centers across North America and Europe, with a focus on indoor cannabis cultivation [9] - In Q1 2025, Hydrofarm reported net sales of $40.5 million, a significant decline attributed to oversupply in cannabis markets, while gross profit margins remained above 20% [10] - The company posted a net loss of $14.4 million but ended the quarter with over $13 million in cash and available credit, focusing on cost discipline and brand consolidation [11] Scotts Miracle-Gro Company (SMG) - Scotts Miracle-Gro, known for lawn and garden care, has a significant role in the cannabis supply chain through its Hawthorne Gardening subsidiary, which focuses on hydroponic equipment and nutrients [12] - In Q2 2025, Scotts reported total sales of $1.42 billion, a decline from the previous year, but gross margins improved to approximately 39% due to cost efficiencies [15] - The company delivered adjusted earnings per share of $3.98, with management reaffirming full-year earnings and cash flow guidance, expecting non-GAAP adjusted EBITDA to reach $570 to $590 million [16] Investment Insights - Ancillary cannabis stocks like GrowGeneration, Hydrofarm, and Scotts Miracle-Gro provide exposure to the cannabis sector without the regulatory risks associated with plant-touching companies [17] - These companies are adapting to weak cultivation demand by focusing on higher-margin products and operational efficiencies, positioning themselves for potential recovery if market conditions improve [18] - Investors should monitor these stocks as they represent different strategies to gain cannabis exposure while managing risk [19]
dsm-firmenich announces increase in share repurchase program to reduce capital to €1 billion
Globenewswire· 2025-06-27 05:00
Core Viewpoint - dsm-firmenich has announced an increase in its share repurchase program to a total of €1.08 billion, following the completion of the sale of its stake in the Feed Enzymes Alliance [1][2]. Group 1: Share Repurchase Program Details - The initial share repurchase program was set at €500 million, which has now been increased to €1.08 billion [1][2]. - The program commenced on April 1, 2025, with an initial amount of €580 million allocated for repurchase, including €80 million for share-based compensation plans [2]. - The increased share repurchase program will be completed no later than January 30, 2026 [2]. Group 2: Execution and Compliance - The share repurchase will be executed in accordance with the Market Abuse Regulation and Swiss law [3]. - dsm-firmenich has engaged a bank to manage the execution of the share repurchase program independently [3]. Group 3: Current Status of Share Repurchase - As of the press release date, approximately 3.6 million ordinary shares have been repurchased, leaving around 8.1 million shares, or 3.0% of ordinary shares issued, still to be repurchased [4]. Group 4: Communication and Reporting - The company will provide weekly updates to the market regarding the progress of the share repurchase program [5].